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Comparison of Different Strategies to 
Measure Medication Adherence via Claims 
Data in Patients With Chronic Heart Failure
Peter Ihle1, Katrin Krueger2, Ingrid Schubert1, Nina Griese-Mammen2, Natalie Parrau2, Ulrich Laufs3 and 
Martin Schulz2,4,*
Medication adherence correlates with morbidity and mortality in patients with chronic heart failure (CHF), but is 
difficult to assess. We conducted a retrospective methodological cohort study in 3,808 CHF patients, calculating 
adherence as proportion of days covered (PDC) utilizing claims data from 2010 to 2015. We aimed to compare 
different parameters’ influence on the PDC of elderly CHF patients exemplifying a complex chronic disease. 
Investigated parameters were the assumed prescribed daily dose (PDD), stockpiling, and periods of hospital stay. 
Thereby, we investigated a new approach using the PDD assigned to different percentiles. The different dose 
assumptions had the biggest influence on the PDC, with variations from 41.9% to 83.7%. Stockpiling and hospital 
stays increased the values slightly. These results queries that a reliable PDC can be calculated with an assumed 
PDD. Hence, results based on an assumed PDD have to be interpreted carefully and should be presented with 
sensitivity analyses to show the PDC’s possible range.
Chronic heart failure (CHF) is associated with high hospital-
ization rates and mortality.1–3 Good medication adherence to 
evidence- based pharmacotherapy is associated with fewer hospi-
talizations and higher patient survival.4,5 However, irregular and 
inconsistent intake of medications is common.4,6 A frequently 
used method to determine medication adherence is the analysis 
of claims data.4,6–10 Claims data are based on billing data with 
additional information. They are characterized by long obser-
vations periods and lack recall bias or interviewer bias. They 
offer insurance- related pseudonymized information on the 
utilization of the health care system. Within the frame of this 
study, International Classification of Diseases, 10th revision (ICD- 
10) coded inpatient and outpatient diagnoses, drug prescriptions, 
and data of hospitalizations are of relevance.
There are different measures and related parameters for the cal-
culation of medication adherence via claims data.8,9 Even though 
there is no gold standard, the medication possession ratio (MPR) 
and the proportion of days covered (PDC) are most commonly 
used.4,7,10,11 However, different definitions and related parameters 
within these methods are used in the literature, e.g., consideration 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 A common method to determine medication adherence is 
the analysis of claims data. These measures are noninvasive, eco-
nomical, and relatively easy to analyze. A crucial point is the 
prescribed daily dose (PDD) but no gold standard exists, if as-
sumptions on the PDD are needed.
WHAT QUESTION DID THIS STUDY ADDRESS?
 The aim of our study was to measure the influence of different 
parameters, assumed PDD, stockpiling, and truncation because of 
hospitalizations on adherence measures in patients with heart fail-
ure exemplifying a complex chronic disease using claims data.
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
 Our results show that it is not feasible to calculate a reliable 
proportion of days covered (PDC) and, consequently, deter-
mine medication adherence, with an assumed PDD.
HOW MIGHT THIS CHANGE CLINICAL PHARMA­
COLOGY OR TRANSLATIONAL SCIENCE?
 Results based on an assumption of the daily doses have to be 
interpreted carefully. If this information is lacking, we recom-
mend to present sensitivity analyses showing a possible range of 
the PDC.
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of the duration of hospital stays and stockpiling (for an overview, 
see Andrade et al.,8 Hess et al.,9 and Vollmer et al.12). Prior to this 
methodological analysis, we performed a systematic literature re-
view on methods and parameters to measure medication adher-
ence via claims data in patients with CHF.4 This systematic review 
discussed recommendations for a feasible method and the needed 
parameters. We identified the following parameters to be consid-
ered for adherence measures via claims data: measurement method, 
observation period, substances, dosing information, switches, 
stockpiling, truncations, statistical analysis, and cutoff for adher-
ence. A crucial point for the adherence measure is the daily dosage 
a patient is advised to take—information not available in many 
claims data.6,10,13–16
Therefore, the aim of this investigation was to perform a meth-
odological analysis to quantitate the influence of dose assumptions, 
stockpiling, and hospital stays on the calculation of the PDC.
RESULTS
Study population
The final study population included 3,808 patients (Table 1). 
The mean age was 80.3 years, 56.3% (n = 2,144) were female, and 
880 patients (23.1%) died during the observation period 2010–
2015. At the time of coding, 8.7% (n = 333) were in New York 
Heart Association (NYHA) class I or II and 53.4% (n = 2,031) in 
NYHA class III or IV (37.9% had no information on the NYHA 
class). The mean Charlson Comorbidity Index was 3.7, indicating 
multimorbidity. Beside diuretics, the most commonly prescribed 
medications were angiotensin converting enzyme inhibitors 
(ACEi) or angiotensin II receptor blockers (ARB), together 89.8% 
and beta- blockers (BB) 81.9%.
Summary of the main results
In relation to the method used, the average PDC varied from 
41.9% to 87.6% for ACEi, 45.6% to 88.8% for ARB, 46.9% to 
89.8% for BB, and 47.8% to 87.6% for mineralocorticoid receptor 
antagonists (MRAs). The different assumptions about the dose 
had a strong influence on PDC. The consideration of stockpiling 
increased the values of the PDC slightly. The consideration of hos-
pital stays had only minor increasing effects.
Influence of the dosing assumptions
The larger the value of the assumed prescribed daily dose (PDD), 
the smaller the calculated PDC. The different assumptions (1.0 
defined daily dose (DDD), one tablet per day, and PDD assigned 
to different percentiles) differ largely in size (Figure 1). This ex-
plains why these different assumptions result in a wide range of 
the PDC (Figure 2).
For example, the PDC for ACEi varied from 41.9% to 81.8% if 
stockpiling and hospital stays were excluded. Using the different 
PDD of the percentiles, the PDC for ACEi increased from 41.9% 
(20th percentile), to 63.4% (50th percentile), to 81.8% (80th 
percentile).
In addition, the different assumed PDD resulted in strongly 
varying values depending on drug class. For the frequently used 
dosing assumption of 1.0 DDD, the values of the PDC varied from 
47.8% for MRA to 80.8% for ACEi, if stockpiling and hospital 
stays were not considered (Table 2). When using one tablet per 
day, the variations between the drug classes were a bit lower but 
still large from 65.6% for MRA to 81.4% for BB. Using the PDD 
assigned to different percentiles, we found very low variations be-
tween the drug classes’ PDC.
Influence of stockpiling
The consideration of stockpiling increased the PDC values for all 
investigated drug classes. As an example with one tablet per day 
and without considering stockpiling and duration of hospital stays, 
the PDC for ACEi was 75.1%, 74.9% for ARB, 81.4% for BB, and 
65.6% for MRA (Table 2). If stockpiling was considered, the PDC 
for ACEi was 80.9%, 81.4% for ARB, 87.3% for BB, and 69.7% for 
MRA (Table 2). The differences in value, caused by stockpiling, 
were similar within the results of the other dosing assumptions.
Influence of hospital stays
The consideration of hospital stays had the lowest influence on 
the PDC, regardless of the variation used. The following results 
refer to the PDC calculation without stockpiling. If the variations 
of hospitalization were considered, the PDC ranged between 
Table 1 Characteristics of the study population (N = 3,808)
Characteristic
Age mean, years (range) 80.3 (60–103)
Female, n (%) 2,144 (56.3)
Deceased, n (%) 880 (23.1)





Classification not coded 1,444 (37.9)
Comorbidities, Charlson score, 
mean ± SD (median)
3.7 ± 2.6 (3)
Mean number of ICD groups, 
mean ± SD (median)
14.7 ± 6.7 (14)
Mean number of hospitalizations, 
mean ± SD (median)
1.5 ± 1.6 (1)
Mean duration of hospitalization 
(days), mean ± SD (median)
14.9 ± 20.1 (8)
Mean number of ATC groups, 
mean ± SD (median)
13.7 ± 5.7 (13)
Diuretics, n (%) 3,808 (100.0)
Beta- blockers, n (%) 3,119 (81.9)
ACEi, n (%) 2,289 (60.1)
Statins, n (%) 1,687 (44.3)
MRA, n (%) 1,615 (42.4)
ARB, n (%) 1,131 (29.7)
Digitalis glycosides, n (%) 990 (26.0)
ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor 
antagonists; ATC, Anatomical Therapeutic Chemical Classification; ICD, 
International Statistical Classification of Diseases and Related Health Problems; 
MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart Association.
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75.5% and 75.6% for ACEi using one tablet per day as daily dose 
(Table 2). In comparison, the PDC was 75.1% without consider-
ation of hospital stays (H0). It differed between 75.3% and 75.5% 
for ARB (H0: 74.9%), between 81.8% and 82.1% for BB (H0: 
81.4%), and between 66.2% and 66.47% for MRA (H0: 65.6%) 
(Table 2). The consideration of hospital stays changed the PDC 
between 0% and 2.8%, depending on the variation.
DISCUSSION
Methods and related parameters to assess medication adherence 
via claims data differ widely in the literature.4,6,8–11 To the best 
of our knowledge, this is the first analysis comparing the influ-
ence of different strategies for the parameters assumed PDD, 
stockpiling, and truncations because of hospitalizations in pa-
tients with CHF.
We found wide variations in the adherence values, in relation 
to the method applied. The average PDC varied from 41.9% to 
89.8%, depending on the method used and the considered drug 
class. The different assumptions about the daily dose had a strong 
influence on the calculated PDC. Stockpiling changed the calcu-
lated PDC values slightly. The duration of hospital stays had only 
a minor effect.
If available, studies used the individual prescribed doses to cal-
culate the PDC.17 If this dose is unknown, no gold standard exists 
for the assumption of the daily doses prescribed. Authors referred 
to the doses of major clinical trials,18 the DDD,13,14,19–21 the doses 
Figure 1 Dose assumptions. Resulted DDD assuming one tablet per day and 20th, 50th, 80th percentiles of the PDD (prescribed daily dose). The 
allocation of the percentiles varied between the drug classes. ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; 
BB, beta- blockers; DDD, defined daily dose; MRA, mineralocorticoid receptor antagonists. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 2 Values of the proportion of days covered (PDC) for the investigated drug classes in relation to the dosing assumptions. Proportion of PDC in 
percent (%) without considering stockpiling and hospital stays. ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; 
BB, beta- blockers; DDD, defined daily dose; MRA, mineralocorticoid receptor antagonists. [Colour figure can be viewed at wileyonlinelibrary.com]
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recommended in each agent’s product monograph,22 or the as-
sumption of one or one or two tablets per day.10,23,24 As for many 
studies analyzing claims data,6,11,13–16,25 the prescribed doses were 
not available in our study. Additionally, the dose recommendations 
by the drug’s product monograph or summary of product charac-
teristics are not explicitly provided for CHF and are incomplete 
for fixed- dosed combinations. Therefore, we made the following 
dose assumptions: 1.0 DDD, one tablet per day as well as a new 
approach by applying different percentiles (20th, 50th, and 80th) 
based on calculated PDD.
The results of the frequently used “DDD- approach” for calcu-
lating the PDC showed marked differences in comparison to the 
other dose assumptions. Many patients using BB or MRA take less 
than one DDD, whereas one DDD is a low dosage for ARB and 
ACEi. The discrepancy between the official DDD and the utili-
zation in real life has also been described by Ude et al.26 This is 
not surprising, since the DDD is a technical unit and not a recom-
mendation for the therapeutic dose. Moreover, the main indication 
to calculate a DDD for these cardiovascular drugs is hypertension, 
instead of CHF.
The other common method is the assumption about one tab-
let per day, irrespective of the prescribed/dispensed drug strength. 
The variation of the PDC’s value between the drug classes were 
lower when assuming one tablet per day than when assuming 1.0 
DDD. The advantage of one tablet is that for each prescription an 
individual dose is used depending on the strength of the dispensed 
drug. One disadvantage of this method is that many patients split 
tablets, as it is often the case for spironolactone. Moreover, some 
drugs are dosed twice (e.g., carvedilol, metoprolol tartrate) or even 
three times a day (e.g., captopril).
We tested a new approach by applying percentiles calculated 
from the claims data per anatomical therapeutic chemical (ATC)- 
group. In contrast to the approaches of 1.0 DDD and one tablet 
per day, the PDD is based on real data of the analyzed population. 
Calculating the PDC with the PDD assigned to percentiles shall 
provide a possible range of the PDC. We decided to use the 20% 
Table 2 Average proportions of days under therapy for the investigated drug classes in relation to the dosing assumption, 
stockpiling, and hospital stays
Drug class Stockpiling Hospital stay
Dose assumption
20th percentile 50th percentile 1 tablet 1.0 DDD 80th percentile
ACEi Without Stockpiling H0 41.9 63.4 75.1 80.8 81.8
H1 42.7 63.8 75.5 81.0 81.9
H2 43.4 64.2 75.6 81.1 82.0
With Stockpiling H0 43.9 68.6 80.9 85.8 86.9
H1 45.9 70.1 82.6 86.6 87.6
H2 46.5 70.3 82.7 86.9 87.6
ARB Without Stockpiling H0 45.6 69.1 74.9 79.7 82.0
H1 46.4 69.5 75.3 79.7 82.1
H2 47.0 69.8 75.5 79.9 82.3
With Stockpiling H0 47.8 73.6 81.4 84.8 87.5
H1 49.8 74.7 83.5 86.6 88.7
H2 50.4 74.9 83.5 86.6 88.8
BB Without Stockpiling H0 46.9 66.5 81.4 53.9 83.7
H1 47.8 67.3 81.8 54.8 84.2
H2 48.6 67.7 82.1 55.5 84.3
With Stockpiling H0 49.3 71.6 87.3 57.4 88.7
H1 51.4 73.4 88.7 59.7 89.7
H2 52.1 73.7 88.8 60.2 89.8
MRA Without Stockpiling H0 47.8 68.1 65.6 47.8 81.9
H1 48.6 68.7 66.2 48.6 82.0
H2 49.0 68.9 66.4 49.0 82.0
With Stockpiling H0 49.6 72.2 69.7 49.6 86.5
H1 51.2 73.7 71.5 51.2 87.6
H2 51.6 73.9 71.7 51.6 87.5
Proportion of days covered (PDC) in percent (%). ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; BB, beta- blockers; DDD, 
defined daily dose; MRA, mineralocorticoid receptor antagonists. H0 = PDC excluding information on hospital stays; H1 = In cases with a dispensing before and 
after discharge (within a period of seven days) the days of hospital stay were calculated as days of adherence; H2 = hospital stays were calculated as days of 
adherence, when a dispensing reaches the first day of hospital stay or starts within seven days after discharge.
ARTICLE
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 106 NUMBER 1 | JULY 2019 215
and 80% extremes of the percentiles as well as the middle 50%. It is 
highly likely that the “real” PDC lies within this range. We found 
very low variations in the values of the PDC of the same percen-
tile between the drug classes. The PDC varied largely between the 
different percentiles, since the 20th and 80th percentiles represent 
extremes of the dosing assumption. One example of ACEi between 
the PDD of the 20th and 80th percentiles is the factor 4 (Figure 1). 
An advantage of this approach is the better comparability of results 
between drug classes compared with the DDD or one tablet per day.
By applying different assumptions of the PDD, we found a 
wide variation in the calculated PDC, both within and between 
drug classes. This holds true when the number of patients with a 
PDC ≥ 80% is determined, a commonly used cutoff for adherence 
(Table S1).
In conclusion, any calculated PDC based on an assumed PDD is 
a rough approximation. Without knowledge of the prescribed dos-
age, it is difficult to calculate a reliable PDC.8,26–28 Most studies 
applied one DDD, a given dose recommendation by the product 
information, or one tablet per day. We demonstrated the uncer-
tainty of these approaches and quantified the impact of different 
dosages on the adherence value by calculating the PDC. For the as-
sumption of different dosages, we are proposing the new percentile 
approach in order to assess the effects quantitatively.
Real- life data support the wide range of daily doses. For exam-
ple, Komajda et al.29 showed that ACEi doses in patients with 
heart failure with reduced ejection fraction vary between 0.9 and 
3 DDD. By assuming a single PDD for a cohort of patients, this 
variation is ignored.
We question that one method of assuming the PDD is the best 
in relation to the real PDD. That is why the results of a PDC based 
on dose assumptions have to be interpreted with great caution.
Studies often do not describe in detail which method and pa-
rameters (prescribed dose?) were used, or the dosing assumption 
is often not stated.4,10,13–16,30–32 Out of 24 papers analyzed in our 
recent review,4 14 did not include information about the used daily 
dose.
If information on the PDD is unavailable, we recommend con-
ducting sensitivity analyses by calculating the PDD based on dif-
ferent assumptions. The result is a possible range of the PDC. The 
reasons for the selection and the advantages and disadvantages of 
the different methods should be discussed.
Some studies allowed stockpiling, thus, the addition of overlap-
ping dispensings.20,21,23 This allows oversupply with the rationale 
that patients get new medication before they have used up their 
previous supply.33 In line with other studies, we observed an in-
creased PDC when allowing stockpiling.9,34,35 Depending on the 
method used, this can lead to an overestimation of medication ad-
herence. Therefore, we recommend a more conservative approach 
and suggest to exclude stockpiling to avoid misjudgments of med-
ication adherence when using a comparable design. This recom-
mendation is supported by the minor influence of stockpiling on 
the PDC.
During a hospital stay, the patient mostly receives the medication 
separately from ambulatory prescriptions. Therefore, many studies 
censored the duration of hospital stays.22,36–42 Hospitalizations 
are frequent in patients with CHF,3 but the length of stay is short 
in relation to the usual observation time of one year. In Germany, 
the average duration of hospitalization for patients with CHF was 
10.4 days in 2015.43 The average length of stay in our study popu-
lation with at least one CHF- related hospitalization in the obser-
vation period up to 12 months was 14.9 days—indicating a sicker 
population. Thereby, we already investigated patients with a long 
hospital stay and found that the days of hospital stays had only a 
minor influence on the PDC. Thus, it seems to be acceptable to 
ignore the duration of hospital stays. However, censoring the dura-
tion of hospital stays increases the precision of the adherence cal-
culation, and that could be important in other populations or for 
specific questions.
Strengths and limitations
The major strength of this study is the characteristic of the 
routine data—above all, including a large number of patients. 
Information is available without interviewer bias or recall bias. 
A selection bias could occur due to the investigation of patients 
insured by only one, although large, health insurance fund. We in-
vestigated a fairly sick population of old (mean age 80 years) CHF 
patients only. For those with data available, more than 50% were 
coded with NYHA stage III or IV. The patients were suffering by 
a variety of comorbidities, and the inclusion criteria included both 
an acute decompensated heart failure hospitalization in the past 
12 months and current use of a diuretic (ATC C03). Hence, the 
PDC data presented are specific for this cohort, although we iden-
tified in a previous systematic review44 older age not to be associ-
ated with poorer medication adherence compared with younger 
(< 60–65 years) CHF patients. However, as the focus of this study 
is on methods, the CHF population is used to exemplify the meth-
odology. Finally, within this study, we did not validate our per-
centiles approach for calculating a PDC against a gold- standard 
measure of adherence, which might be a combination of therapeu-
tic drug or electronic monitoring and a self- report questionnaire.
CONCLUSIONS
The assessment of medication adherence is important for both 
research and clinical practice.9,45 Claims data represent an often 
easily accessible source to assess medication adherence. By using 
the PDC method, we investigated the influence of different as-
sumptions for the parameters dosing (expressed as DDD, number 
of daily tablets, or assumed PDDs), stockpiling, and truncations 
because of hospitalizations in CHF patients. It seems to be appro-
priate to exclude stockpiling and to ignore the duration of hospital 
stays calculating adherence for patients with CHF. The different 
methods of assuming the PDD leads to significant differences in 
the PDC. It seems impossible that a reliable PDC can be calcu-
lated without individual dosing instructions. If information on the 
individual PDD is lacking, we recommend to present sensitivity 
analyses showing a possible range of the PDC. The new approach 
by applying percentiles makes it possible to calculate such a range.
METHODS
Data set
We used a 10% sample of the Germany- wide pseudonymized data of a 
large statutory health insurance fund (Barmer GEK, insuring ~ 9.4 
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million persons in 2015), from 2010 to 2015. The data contained claims 
data of prescribed drugs, dispensed at community pharmacies, as well as 
data related to patients’ sex and gender, ICD- 10 German Modification 
coded outpatient and inpatient diagnoses, hospitalizations, and deaths. 
For prescribed drugs, the information on the ingredient (ATC code), the 
dosage per unit (strength), and the package size are available. In addi-
tion, the date of issuing the prescription and the date of dispensing at the 
pharmacy are available. For each dispensing, a new prescription has to be 
issued. The database contains no information on the number of drugs 
to be taken by the patient. Moreover, information on over- the- counter 
medication, medications dispensed at a hospital stay, and clinical data 
were not available.
Study design
Based on the findings of our systematic review for a feasible method and the 
needed parameters,4 we conducted a retrospective methodological cohort 
study to compare the influence of different strategies regarding the assumed 
PDD, stockpiling, and truncations because of hospitalizations on the PDC. 
We considered the recommendations on Good Practice for Secondary Data 
Analyses,46 and the checklist published by the International Society for 
Pharmacoeconomics and Outcome Research (ISPOR).7
Relevant parameters
We defined the following parameters for the operationalization of the 
adherence measurement: the PDC as the measurement method, 365 days 
as the observation period, and the consideration of typical CHF med-
ications. We allowed switching within a therapeutic class. Deceased 
patients were censored and considered until death occurred. Different 
assumptions regarding the daily dose, stockpiling, and truncations due 
to hospitalizations were assessed.
Inclusion and exclusion criteria
The inclusion and exclusion criteria were determined following the study 
population of major clinical trials on CHF.47–49 We included patients 
with a discharge diagnosis of CHF (ICD- Code “I50”) in the index 
quarter or an assured outpatient diagnosis, aged 60 years and older, and 
with a hospitalization for CHF in the last 12 months before inclusion. 
Additionally, patients had to have at least one dispensing of any diuretic 
(ATC C03) before inclusion but lasting into the index quarter by calcu-
lating the coverage with one defined daily dose (DDD).19 Patients who 
died in the index quarter were excluded.
Drugs included in the analyses were ACEi (ATC codes C09A, C09B), 
ARB (C09C, C09D), BB (C07), and MRA (C03DA, C03EC, C03ED). 
All medications dispensed before the index quarter but extending into the 
observation period were included in the calculation.
Calculation of medication adherence
Adherence was calculated using the PDC, which is the ratio of number of 
days in the period covered by a medicine (numerator) to the total number 
of days in the observation period (denominator).7
Observation period. For every patient, the first day of therapy could be 
either the first day of the observation period (in cases with coverage of 
the drug from the preindex period) or the day of the first prescription in 
the observation period. The study period ended after 365 days or at the 
time of death. The observation period (denominator) was the number 
of days from the first day of therapy until the last day of the observation 
period.
Days covered. The calculation of the number of days covered with 
medication between the first and the last day of the observation period 
was determined (numerator) with different strategies regarding the 
assumed PDD, stockpiling, and the duration of hospital stays.
Finally, we used 30 different variations of these strategies to calculate 
the PDC: five dose assumptions, three considerations regarding hospital 
stays, and two regarding stockpiling.
Dosing assumptions. The PDD of a drug is required to determine the 
number of days covered out of a drug’s dispensing. This information is 
not available in many claims databases.6,10,13–16
We made the following assumptions about the PDD:
1. One DDD is the “average maintenance dose per day for a drug 
used for its main indication in adults.”50 Assuming the DDD 
as PDD, the days covered were calculated by using the DDD’s 
specified amount in mg as daily dose.
2. Assuming one tablet per day as PDD, the days covered were calculated 
by using the number of tablets prescribed/dispensed. Thereby, one 
tablet prescribed/dispensed resulted in one day covered.
3. A calculated PDD assigned to the 20th, 50th, and 80th percentiles. 
The 20th, 50th, and 80th percentiles represent the total dispensings’ 
portion that shows a coverage until the next prescription/dispensing 
or beyond using this respective PDD. To calculate the PDD for a dis-
pensing with a given dispensing date as starting point, we needed an 
ending date which is the date of the following dispensing event. 
Defining that the total drug’s amount of the first dispensing was suf-
ficient until the second dispensing, the PDD was calculated as the 
drug’s amount of the respective dispensing event divided by the num-
ber of days until the second dispensing. For example, there was a dis-
pensing of 50 tablets with a dosage strength of 25 mg and a second 
dispensing of that drug after 60 days. We then divided the total drug 
amount of that dispensing (50 tablets × 25 mg = 1,250 mg) by 60 days, 
which would result in a PDD of 20.83 mg. After calculating the PDD 
of every dispensing with a following dispensing, the PDD’s percentiles 
were depicted per ATC group and by sorting the dispensing periods by 
PDD downward and percentile ranked. The PDD values of the 20th, 
50th, and 80th percentiles were used for further analyses.
When using the PDD of a corresponding percentile to calculate the 
coverage of a dispensing, the corresponding percentile represents the total 
dispensings’ portion that shows a coverage until the next dispensing or 
beyond. The result is that the smaller the PDD used for the calculation 
of coverage, the higher the number of days covered by a dispensing, and 
the bigger the total dispensings’ portion with coverage until the next dis-
pensing or beyond. Therefore, the bigger the percentile, the smaller the 
corresponding PDD. We used the PDD of the 20th, 50th, and 80th per-
centiles. The 80th percentile represents the daily dose’s lower range, the 
20th percentile the upper range, respectively.
In order to compare the different dose assumptions, they each were 
converted into the corresponding DDD (Figure 1). For converting the 
assumption about one tablet per day in a corresponding DDD, the mean 
strength of all prescribed tablets of one ATC group was calculated.
Consideration of stockpiling. With each dose assumption, the number 
of days covered for each dispensing was calculated. If the subsequent 
dispensing occurred before the end of coverage by the previous 
dispensing, adherence calculation was performed with and without 
stockpiling. Stockpiling describes the extension of a dispensing if there 
were residues of the last dispensing, thus the addition of overlapping 
dispensings. In the scenario without stockpiling we censored residues. 
We extended the residues of a dispensing in the scenario with stockpiling 
i.e., we moved the start of the subsequent dispensing until the end of the 
previous.
Consideration of hospital stays. Regarding the influence of hospital 
stays on the PDC, we applied different scenarios, whether days in hospital 
were taken into account as days covered:
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Scenario “H1”: Days in hospital are considered as days covered, if 
the coverage of a dispensing reached the first day of the hospital 
stay, and a subsequent dispensing within seven days after hospital 
discharge was detected.
Scenario “H2”: Days in hospital are considered as days covered, if 
the coverage reached the first day of the hospital stay or a dispens-
ing started within seven days after discharge.
Additionally, we calculated adherence ignoring days in hospital 
(H0), resulting in three different variations of consideration re-
garding hospital stays.
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